We conducted a multicenter , phase II , randomized trial including patients with secondary progressive or relapsing-remitting MS , with a documented increase in the last year on the Expanded Disability Status Scale , in spite of conventional therapy , and presence of one or more gadolinium-enhancing ( Gd + ) areas .